

# Osteoporosis in Women Who Had a Fracture

wellcare

At Wellcare, we value everything you do to deliver quality care to our members – your patients. We appreciate your commitment to their positive healthcare experience. That’s why we’re asking you to join us in efforts to help improve patient outcomes and quality scores!

Time Sensitive Quality Measure	Action Needed
The CMS Stars quality measure, <b><i>Osteoporosis in Women Who Had a Fracture</i></b> , evaluates the percentage of women aged 67–85 years who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat osteoporosis within <b>six months</b> of the fracture.	To view the tiering and full formulary list of medications, please visit our website at <b>www.wellcare.com</b> ; or assist the member with getting a BMD test within <b>six months</b> of the fracture. Submit applicable codes. See below.



## General Principles of Osteoporosis Treatment

- ✓ Central Dual-energy X-rayabsorptiometry (DXA) assessment is the “gold standard” for serial assessment of BMD
- ✓ Postmenopausal women and men age 50 and older presenting with the following should be considered for treatment: a hip or vertebral fracture (clinically apparent or found on vertebral imaging) or osteoporosis by DXA.
- ✓ Patients taking FDA-approved medications should have laboratory and bone density re-evaluation every 1 to 3 years (more frequently when medically appropriate).
- ✓ Review the need for continued medication each year.
- ✓ Treatment duration should be individualized.
- ✓ Verify whether patients are taking their medications. Encourage continued and appropriate adherence with therapies to reduce fracture risk.
- ✓ It is also important to review their risk factors and encourage appropriate calcium and vitamin D intakes, exercise, fall prevention, and other lifestyle measures.

We recognize that you are best qualified to evaluate the potential risks and benefits in choosing the most appropriate medications for your patients. **Thank you for your continued dedication to our members’ best health.**



## OMW – Osteoporosis Management

**Codes:** 76977, 77078, 77080, 77081, 77085, 77086, J0897, J1740, J3110, J3111, J3489

Reference: Eastell R, Rosen C, Black D, et al. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society\* Clinical Practice Guideline. J Clin Endocrinol Metab. (2019);104:1595-1622.

PRO\_1939054E Internal Approved 03172023

©Wellcare 2023

1939054\_NA3PCARFLYE